Table 1.
Results of the hormonal, histological and expression of ovarian Bcl-2 and Bax proteins four weeks after treatment
| Groups | Control | BMSCs | L-carnitine | BMSC+L-carnitine |
|---|---|---|---|---|
| E2 (pg/ml) | 25.18 ± 1.769 | 40.74 ± 0.63*** | 31.48 ± 0.533** | 45.2 ± 0.728*** |
| FSH (mIU/ml) | 14.34 ± 0.682 | 6.9 ± 0.24*** | 10.5 ± 0.791** | 4.62 ± 0.338*** |
| The number of ovarian follicles in different stages | ||||
| Primordial | 17 ± 1.581 | 28.2 ± 0.86*** | 23.6 ± 0.51** | 33.2 ± 0.583*** |
| Primary | 14.4 ± 0.748 | 25.4 ± 0.678*** | 20 ± 0.707** | 30 ± 1.03*** |
| Secondary | 13 ± 0.316 | 20 ± 0.707*** | 17.4 ± 0.748** | 25.2 ± 0.583*** |
| Antral | 5.6 ± 0.51 | 13.6 ± 0.51*** | 9.4 ± 0.61** | 18.2 ± 0.583*** |
| Expression of ovarian Bcl-2 protein | 1.0 ± 0.0 | 1.473 ± 0.017*** | 1.89 ± 0.054* | 2.347 ±0.167*** |
| Expression of ovarian Bax protein | 1.0 ± 0.0 | 0.806 ± 0.011*** | 0.392 ± 0.051** | 0.179 ± 0.027*** |
| Bcl-2/Bax ratio | 0.723 ± 0.047 | 1.12 ± 0.026* | 1.143 ± 0.046* | 4.018 ± 0.127*** |
Data are presented as mean ± SE. E2; Estradiol, FSH; Follicle-stimulating hormone, *; P<0.05, **; P<0.01, and ***; P<0.001 versus control group.